Antipsychotic-Induced Insulin Resistance and Postprandial Hormonal Dysregulation Independent of Weight Gain or Psychiatric Disease
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Atypical antipsychotic (AAP) medications that have revolutionized the treatment of mental illness have become stigmatized by metabolic side effects, including obesity and diabetes. It remains controversial whether the defects are treatment induced or disease related. Although the mechanisms underlying these metabolic defects are not understood, it is assumed that the initiating pathophysiology is weight gain, secondary to centrally mediated increases in appetite. To determine if the AAPs have detrimental metabolic effects independent of weight gain or psychiatric disease, we administered olanzapine, aripiprazole, or placebo for 9 days to healthy subjects (n = 10, each group) under controlled in-patient conditions while maintaining activity levels. Prior to and after the interventions, we conducted a meal challenge and a euglycemic-hyperinsulinemic clamp to evaluate insulin sensitivity and glucose disposal. We found that olanzapine, an AAP highly associated with weight gain, causes significant elevations in postprandial insulin, glucagon-like peptide 1 (GLP-1), and glucagon coincident with insulin resistance compared with placebo. Aripiprazole, an AAP considered metabolically sparing, induces insulin resistance but has no effect on postprandial hormones. Importantly, the metabolic changes occur in the absence of weight gain, increases in food intake and hunger, or psychiatric disease, suggesting that AAPs exert direct effects on tissues independent of mechanisms regulating eating behavior.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In psychiatry, iatrogenesis has traditionally been concerned with medical complications of psychotropic drug treatment [3], such as tardive dyskinesia [4] and insulin resistance [5] with antipsychotic drugs, and cardiac and metabolic disturbances with antidepressant medications [6][7][8].”
From Iatrogenic Factors in Psychopathology (2019) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139
(1998) · PubMed · Cited by 10,216
The mini international neuropsychiatric interview
Lecrubier, Y., Sheehan, D., Hergueta, T., & Weiller, E. (1998) · European Psychiatry · doi:10.1016/s0924-9338(99)80239-9 · Cited by 5,872
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382 · cited 2×
“Over the past decade, there has been increasing recognition that some of the second-generation antipsychotic medications, termed the atypical antipsychotics (AAPs), are associated with an increased incidence of obesity (1), type 2 diabetes (2,3), and cardiovascular disease (4,5).”
BackgroundThe biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210 · cited 2×
“However, elevations in GLP-1 coincident with insulin resistance and increases in glucagon are surprising since GLP-1 inhibits glucagon release (37) and is attenuated in type 2 diabetes (38).”
BackgroundMcEvoy, J. P., Meyer, J. M., Goff, D. C., Nasrallah, H. A., Davis, S. M., Sullivan, L., Meltzer, H. Y., Hsiao, J., Scott Stroup, T., & Lieberman, J. A. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.07.014 · Cited by 1,140 · cited 1×
“Aripiprazole tends to cause less weight gain than olanzapine (15) and is often considered metabolically neutral (16–18).”
BackgroundAssessment of Insulin Sensitivity in Vivo*
Bergman, R. N., Finegood, D. T., & Ader, M. (1985) · Endocrine Reviews · doi:10.1210/edrv-6-1-45 · Cited by 1,066 · cited 8×
“Preintervention, postprandial glucose levels were not significantly different across treatments (F(2,27) = 0.”
BackgroundResultInfluentialCorrell, C. U. (2009) · JAMA · doi:10.1001/jama.2009.1549 · Cited by 1,050 · cited 1×
“The implications for public health are tremendous (6) due to the large number of adult patients treated with these agents and the increasing use of off-label prescriptions to children (7) and the elderly (8).”
BackgroundVilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884 · cited 1×
“However, elevations in GLP-1 coincident with insulin resistance and increases in glucagon are surprising since GLP-1 inhibits glucagon release (37) and is attenuated in type 2 diabetes (38).”
BackgroundGlucocorticoids and insulin resistance: old hormones, new targets
ANDREWS, R. C., & WALKER, B. R. (1999) · Clinical Science · doi:10.1042/cs0960513 · Cited by 731 · cited 1×
“Two important variables that will be measured in future studies are glucose-dependent insulinotropic peptide, known to enhance insulin secretion (47), and cortisol, which can induce insulin resistance (48).”
BackgroundAtypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles
Nasrallah, H. A. (2008) · Molecular Psychiatry · doi:10.1038/sj.mp.4002066 · Cited by 714 · cited 2×
“Based on these data and data from our own laboratory showing that vagally mediated, early phase insulin can be inhibited by muscarinic blockade (36), we (42) and others (40,43,44) speculated that olanzapine induces metabolic impairments by attenuating insulin release through muscarinic blockade.”
BackgroundFree Fatty Acids and Pathogenesis of Type 2 Diabetes Mellitus
BERGMAN, R., & ADER, M. (2000) · Trends in Endocrinology and Metabolism · doi:10.1016/s1043-2760(00)00323-4 · Cited by 622 · cited 2×
“Insulin resistance is typically characterized by elevations in EGP and circulating FFAs (31,32), but we did not find changes in either variable after AAP administration.”
BackgroundC-Peptide as a Measure of the Secretion and Hepatic Extraction of Insulin: Pitfalls and Limitations
Polonsky, K. S., & Rubenstein, A. H. (1984) · Diabetes · doi:10.2337/diab.33.5.486 · Cited by 476
Metabolic considerations in the use of antipsychotic medications: a review of recent evidence.
Newcomer, J. W. (2007) · PubMed · Cited by 380
Kim, S. P., Ellmerer, M., Kirkman, E. L., & Bergman, R. N. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00351.2006 · Cited by 272 · cited 1×
“Changes in hepatic insulin clearance are increasingly being recognized as an important mechanism contributing to glucose homeostasis in insulin resistance (30).”
BackgroundGlucocorticoids and insulin resistance: old hormones, new targets
Andrews, R. C., & Walker, B. R. (1999) · Clinical Science · doi:10.1042/cs19980388 · Cited by 266
Which comes first: atypical antipsychotic treatment or cardiometabolic risk?
Stahl, S. M., Mignon, L., & Meyer, J. M. (2009) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2008.01334.x · Cited by 259 · cited 1×
“Based on these data and data from our own laboratory showing that vagally mediated, early phase insulin can be inhibited by muscarinic blockade (36), we (42) and others (40,43,44) speculated that olanzapine induces metabolic impairments by attenuating insulin release through muscarinic blockade.”
BackgroundGlucagonlike peptide 1: a newly discovered gastrointestinal hormone
Holst, J. J. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90831-1 · Cited by 252 · cited 1×
“We had hypothesized that meal ingestion, which elicits incretin responses (33,34) and neurally mediated insulin release (35,36), would be more likely to unveil the effects of FIG.”
BackgroundDaumit, G. L., Goff, D. C., Meyer, J. M., Davis, V. G., Nasrallah, H. A., McEvoy, J. P., Rosenheck, R., Davis, S. M., Hsiao, J. K., Stroup, T. S., et al. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.07.006 · Cited by 223 · cited 1×
“Over the past decade, there has been increasing recognition that some of the second-generation antipsychotic medications, termed the atypical antipsychotics (AAPs), are associated with an increased incidence of obesity (1), type 2 diabetes (2,3), and cardiovascular disease (4,5).”
BackgroundNielsen, J., Skadhede, S., & Correll, C. U. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.78 · Cited by 207
Basu, R., Chandramouli, V., Dicke, B., Landau, B., & Rizza, R. (2005) · Diabetes · doi:10.2337/diabetes.54.7.1942 · Cited by 189 · cited 2×
“Insulin resistance is typically characterized by elevations in EGP and circulating FFAs (31,32), but we did not find changes in either variable after AAP administration.”
BackgroundImpact of Substance Use Disorder on ADHD and Its Treatment
Wilens, T. E., & Upadhyaya, H. P. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.0807e20 · Cited by 188
Patel, J. K., Buckley, P. F., Woolson, S., Hamer, R. M., McEvoy, J. P., Perkins, D. O., Lieberman, J. A., & for the CAFE investigators (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.03.025 · Cited by 169 · cited 13×
“Here we show that short-term administration of the AAPs olanzapine and aripiprazole induces insulin resistance in healthy subjects, but only olanzapine results in significant changes in postprandial metabolism after a mixed-meal challenge.”
BackgroundInfluentialMetabolism of C-peptide in the dog. In vivo demonstration of the absence of hepatic extraction.
Polonsky, K., Jaspan, J., Pugh, W., Cohen, D., Schneider, M., Schwartz, T., Moossa, A. R., Tager, H., & Rubenstein, A. H. (1983) · Journal of Clinical Investigation · doi:10.1172/jci111036 · Cited by 158 · cited 1×
“insulin clearance (28,29), the observed decrease in the ratio after AAPs may be due to decreases in hepatic insulin clearance compensatory to prevailing insulin resistance.”
BackgroundStrassnig, M., Miewald, J. M., Keshavan, M. S., & Ganguli, R. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.02.024 · Cited by 135 · cited 13×
“Here we show that short-term administration of the AAPs olanzapine and aripiprazole induces insulin resistance in healthy subjects, but only olanzapine results in significant changes in postprandial metabolism after a mixed-meal challenge.”
BackgroundInfluentialAbnormalities of glucose metabolism associated with atypical antipsychotic drugs.
Newcomer, J. W. (2004) · PubMed · Cited by 132
Johnson, D. E., Yamazaki, H., Ward, K. M., Schmidt, A. W., Lebel, W. S., Treadway, J. L., Gibbs, E. M., Zawalich, W. S., & Rollema, H. (2005) · Diabetes · doi:10.2337/diabetes.54.5.1552 · Cited by 132 · cited 1×
“Olanzapine has been shown to be a high-affinity muscarinic receptor antagonist (40) and in vitro can block acetylcholine binding to muscarinic receptors on the pancreatic islet, thereby inhibiting insulin release (41).”
BackgroundSowell, M. O. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.6.2918 · Cited by 129
Teff, K. L., & Engelman, K. (1996) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1996.270.6.r1371 · Cited by 129 · cited 1×
“We had hypothesized that meal ingestion, which elicits incretin responses (33,34) and neurally mediated insulin release (35,36), would be more likely to unveil the effects of FIG.”
BackgroundSelf-citationAlbaugh, V. L., Singareddy, R., Mauger, D., & Lynch, C. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022662 · Cited by 118 · cited 3×
“Olanzapine-induced increases in postprandial insulin have not previously been documented, but investigation has been limited to studies that had insufficient postmeal sampling frequency (20) or did not use a mixednutrient stimulus (24).”
Effects of Olanzapine and Ziprasidone on Glucose Tolerance in Healthy Volunteers
Sacher, J., Mossaheb, N., Spindelegger, C., Klein, N., Geiss-Granadia, T., Sauermann, R., Lackner, E., Joukhadar, C., Müller, M., & Kasper, S. F. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301541 · Cited by 108 · cited 1×
“A handful of studies have used this approach, reporting either no effect (19–21) or decreases in insulin sensitivity in the presence of modest weight gain after short-term administration (10–15 days) of olanzapine compared with other AAPs or placebo (22).”
BackgroundIncreased Food Intake and Energy Expenditure Following Administration of Olanzapine to Healthy Men
Fountaine, R. J., Taylor, A. E., Mancuso, J. P., Greenway, F. L., Byerley, L. O., Smith, S. R., Most, M. M., & Fryburg, D. A. (2010) · Obesity · doi:10.1038/oby.2010.6 · Cited by 99
Effects of Olanzapine and Haloperidol on the Metabolic Status of Healthy Men
Vidarsdottir, S., de Leeuw van Weenen, J. E., Frölich, M., Roelfsema, F., Romijn, J. A., & Pijl, H. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1815 · Cited by 91 · cited 1×
“Weightindependent effects in control subjects have only been reported in two studies, with olanzapine decreasing insulin sensitivity (23) and increasing fasting glucose and leptin after an oral glucose tolerance test (24).”
Hahn, M., Chintoh, A. F., Giacca, A., Xu, L., Lam, L., Mann, S. W., Fletcher, P. J., Guenette, M. D., Cohn, T. A., Wolever, T., et al. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.06.004 · Cited by 84 · cited 1×
“Based on these data and data from our own laboratory showing that vagally mediated, early phase insulin can be inhibited by muscarinic blockade (36), we (42) and others (40,43,44) speculated that olanzapine induces metabolic impairments by attenuating insulin release through muscarinic blockade.”
BackgroundMeyer, J. M., Davis, V. G., McEvoy, J. P., GOFF, D. C., Nasrallah, H. A., Thomas, S., Daumit, G. L., Hsiao, J., Swartz, M. S., Stroup, T. S., et al. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.04.023 · Cited by 80 · cited 1×
“Olanzapine, a well-tolerated and highly effective agent, is associated with some of the most severe metabolic consequences, including weight gain and increases in fasting glucose, insulin (11,12), and lipids (13,14).”
BackgroundUnraveling the Science of Incretin Biology
Nauck, M. A. (2009) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2009.05.012 · Cited by 74 · cited 1×
“Two important variables that will be measured in future studies are glucose-dependent insulinotropic peptide, known to enhance insulin secretion (47), and cortisol, which can induce insulin resistance (48).”
BackgroundCharacterization of GLP-1 Effects on β-Cell Function After Meal Ingestion in Humans
Ahrén, B., Holst, J. J., & Mari, A. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2860 · Cited by 72 · cited 1×
“We had hypothesized that meal ingestion, which elicits incretin responses (33,34) and neurally mediated insulin release (35,36), would be more likely to unveil the effects of FIG.”
BackgroundSowell, M., Mukhopadhyay, N., Cavazzoni, P., Carlson, C., Mudaliar, S., Chinnapongse, S., Ray, A., Davis, T., Breier, A., Henry, R. R., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021884 · Cited by 69 · cited 1×
“Olanzapine-induced increases in postprandial insulin have not previously been documented, but investigation has been limited to studies that had insufficient postmeal sampling frequency (20) or did not use a mixednutrient stimulus (24).”
BackgroundRosenheck, R., LESLIE, D. L., & Sernyak, M. J. (2001) · Medical Care · doi:10.1097/00005650-200103000-00010 · Cited by 68 · cited 1×
“The implications for public health are tremendous (6) due to the large number of adult patients treated with these agents and the increasing use of off-label prescriptions to children (7) and the elderly (8).”
BackgroundEarly phase insulin infusion and muscarinic blockade in obese and lean subjects
Teff, K. L., & Townsend, R. R. (1999) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1999.277.1.r198 · Cited by 68 · cited 3×
“Based on these data and data from our own laboratory showing that vagally mediated, early phase insulin can be inhibited by muscarinic blockade (36), we (42) and others (40,43,44) speculated that olanzapine induces metabolic impairments by attenuating insulin release through muscarinic blockade.”
BackgroundSelf-citationAtypical antipsychotics and the neural regulation of food intake and peripheral metabolism
Teff, K. L., & Kim, S. F. (2011) · Physiology & Behavior · doi:10.1016/j.physbeh.2011.05.033 · Cited by 67 · cited 1×
“Based on these data and data from our own laboratory showing that vagally mediated, early phase insulin can be inhibited by muscarinic blockade (36), we (42) and others (40,43,44) speculated that olanzapine induces metabolic impairments by attenuating insulin release through muscarinic blockade.”
BackgroundSelf-citationCardiovascular effects of antipsychotics
Michelsen, J. W., & Meyer, J. M. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.7.829 · Cited by 64 · cited 1×
“Over the past decade, there has been increasing recognition that some of the second-generation antipsychotic medications, termed the atypical antipsychotics (AAPs), are associated with an increased incidence of obesity (1), type 2 diabetes (2,3), and cardiovascular disease (4,5).”
BackgroundHenderson, D. C., Copeland, P. M., Borba, C. P., Daley, T. B., Nguyen, D. D., Cagliero, E., Evins, A. E., Zhang, H., Hayden, D. L., Freudenreich, O., et al. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0513 · Cited by 57 · cited 1×
“Olanzapine, a well-tolerated and highly effective agent, is associated with some of the most severe metabolic consequences, including weight gain and increases in fasting glucose, insulin (11,12), and lipids (13,14).”
BackgroundHaupt, D. W., Fahnestock, P. A., Flavin, K. S., Schweiger, J. A., Stevens, A., HESSLER, M. J., Maeda, J. A., Yingling, M. D., & Newcomer, J. W. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301392 · Cited by 54 · cited 1×
“Olanzapine, a well-tolerated and highly effective agent, is associated with some of the most severe metabolic consequences, including weight gain and increases in fasting glucose, insulin (11,12), and lipids (13,14).”
BackgroundAssessment of postprandial glucose metabolism: conventional dual- vs. triple-tracer method
Toffolo, G., Basu, R., Dalla Man, C., Rizza, R., & Cobelli, C. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00461.2005 · Cited by 51 · cited 2×
“Once cooled to room temperature, [1-(13)C]glucose was added to obtain an enrichment of 4% (26).”
BackgroundMethodBasu, A., & Meltzer, H. Y. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.04.014 · Cited by 46 · cited 1×
“Over the past decade, there has been increasing recognition that some of the second-generation antipsychotic medications, termed the atypical antipsychotics (AAPs), are associated with an increased incidence of obesity (1), type 2 diabetes (2,3), and cardiovascular disease (4,5).”
BackgroundVidarsdottir, S., Roelfsema, F., Streefland, T., Holst, J. J., Rehfeld, J. F., & Pijl, H. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-0433 · Cited by 37 · cited 1×
“Elevated postprandial GLP-1 has not previously been observed after olanzapine administration; although there is one negative report (39).”
BackgroundTeff, K. L., & Townsend, R. R. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032094 · Cited by 30 · cited 1×
“As vagally mediated insulin secretion can be induced by changes in peripheral metabolism (45), and olanzapine has been shown to exert procholinergic effects independent of muscarinic antagonism (46), we now speculate that antagonism of peripheral muscarinic receptors may result in a compensatory centrally mediated inc…”
BackgroundSelf-citationWang, L., Ree, S., Huang, Y., Hsiao, C., & Chen, C. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.10.010 · Cited by 27
Gianfrancesco, F. D., Pesa, J. A., Wang, R., & Nasrallah, H. A. (2006) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp050144 · Cited by 25 · cited 8×
“Over the past decade, there has been increasing recognition that some of the second-generation antipsychotic medications, termed the atypical antipsychotics (AAPs), are associated with an increased incidence of obesity (1), type 2 diabetes (2,3), and cardiovascular disease (4,5).”
BackgroundResultInfluentialGanguli, R., Brar, J., Garbut, R., Chang, C.-C., & Basu, R. (2011) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.5.2.3 · Cited by 19
Tzavara, E. T., Bymaster, F. P., & Nomikos, G. G. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001834 · Cited by 8 · cited 1×
“As vagally mediated insulin secretion can be induced by changes in peripheral metabolism (45), and olanzapine has been shown to exert procholinergic effects independent of muscarinic antagonism (46), we now speculate that antagonism of peripheral muscarinic receptors may result in a compensatory centrally mediated inc…”
Background
Cited by
Trends in insulin resistance: insights into mechanisms and therapeutic strategy
Li, M., Chi, X., Wang, Y., Setrerrahmane, S., Xie, W., & Xu, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01073-0 · Cited by 939
Atypical Antipsychotics and Metabolic Syndrome: From Molecular Mechanisms to Clinical Differences
Carli, M., Kolachalam, S., Longoni, B., Pintaudi, A., Baldini, M., Aringhieri, S., Fasciani, I., Annibale, P., Maggio, R., & Scarselli, M. (2021) · Pharmaceuticals · doi:10.3390/ph14030238 · Cited by 250
“with compensatory stimulation of the β-cells [63,89].”
Role of endoplasmic reticulum stress in drug‐induced toxicity
Foufelle, F., & Fromenty, B. (2016) · Pharmacology Research & Perspectives · doi:10.1002/prp2.211 · Cited by 246
“However, the pathophysiological significance of this effect remains unclear since this drug classically induces hyperinsulinemia, even in the absence of weight gain (Melkersson and Dahl 2003; Teff et al. 2013).”
BackgroundInteraction Between Atypical Antipsychotics and the Gut Microbiome in a Bipolar Disease Cohort
Flowers, S. A., Evans, S. J., Ward, K. M., McInnis, M. G., & Ellingrod, V. L. (2017) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1890 · Cited by 235
“Data suggest that in response to AAPs without increases in BMI, both human and animal models incur metabolic phenotypes such as glucose dysregulation.(27) This makes the decreased relative abundance of A.”
BackgroundThe antipsychotic olanzapine interacts with the gut microbiome to cause weight gain in mouse
Morgan, A. P., Crowley, J. J., Nonneman, R. J., Quackenbush, C. R., Miller, C. N., Ryan, A. K., Bogue, M. A., Paredes, S. H., Yourstone, S., Carroll, I. M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115225 · Cited by 197
Metadata
- Authors
- Teff, K. L., Rickels, M. R., Grudziak, J., Fuller, C., Nguyen, H.-L., & Rickels, K.
- Affiliations
- Monell Chemical Senses Center (US)
- University of Pennsylvania (US)
- Corresponding author
- Teff, Karen L.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2013-08-15
- Volume
- 62
- Issue
- 9
- Pages
- 3232-3240
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC3749337
- OpenAlex
- W2126815601
- Cited by
- 195
- References
- 51
- Citations by year
- 2026: 12 · 2025: 13 · 2024: 14 · 2023: 10 · 2022: 14 · 2021: 15 · 2020: 12 · 2019: 12 · 2018: 21 · 2017: 15 · 2016: 18 · 2015: 19 · 2014: 15 · 2013: 5
- FWCI
- 13.46
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- American Diabetes Association
- University of Pennsylvania
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases (DK 19525, R01DK084383, DK084383, P30DK019525)
- National Center for Research Resources (UL1RR024134)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- atypical antipsychotics, insulin resistance, olanzapine, aripiprazole, postprandial insulin, glucagon-like peptide-1, glucagon, glucose disposal, insulin sensitivity, metabolic side effects, weight gain, appetite, hyperinsulinemic-euglycemic clamp, meal challenge
- MeSH terms
- Aripiprazole, Olanzapine, Adult, Mental Disorders, Benzodiazepines, Eating, Female, Humans, Insulin Resistance, Male, Piperazines, Antipsychotic Agents, Quinolones, Weight Gain, Postprandial Period, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.